GLP1R and Alzheimer disease: Recently, AD has been recognized as type 3 diabetes occurring in the brain, and anti-diabetic peptide drugs, such as insulin and glucagon-like peptide-1 (GLP-1) receptor agonists, have been suggested to enhance memory and learning via insulin receptor signaling and resultant glucose uptake into the hippocampal neuronal cells7–15.